Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer
July 11, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., July 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
Argos Therapeutics Announces Closing of $29.8 Million Second Tranche of March 2016 Financing
June 29, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., June 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
Argos Therapeutics Added to the Russell 2000® Index
June 27, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., June 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
Argos Therapeutics Enters into Strategic Research Agreement with Adaptive Biotechnologies
June 15, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., June 15, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review
June 13, 2016 08:00 ET
|
Argos Therapeutics Inc.
Positive outcome triggers the second tranche of the Company’s previously announced financing agreement Argos Therapeutics to host conference call with the trial’s co-principal investigator,...
Argos Therapeutics to Participate in Jefferies 2016 Healthcare Conference
June 08, 2016 16:05 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., June 08, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
May 12, 2016 16:05 ET
|
Argos Therapeutics, Inc.
- Entered into Equity Financing for Up to $60 million - - Phase 3 ADAPT trial of AGS-003 in Metastatic Renal Cell Carcinoma On Track for Upcoming Review by Independent Data Monitoring...
Argos Therapeutics to Participate in World Stem Cells and Regenerative Medicine Congress
May 11, 2016 16:05 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
Argos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016
May 05, 2016 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., May 05, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized...
Argos Therapeutics to Participate in 15th Annual Needham Healthcare Conference
April 07, 2016 16:05 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., April 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...